Chronic infections resulting from biofilm formation are difficult to eradicate with current antimicrobial agents and consequently new therapies are needed. This work demonstrates that the carbon monoxide-releasing molecule CORM-2, previously shown to kill planktonic bacteria, also attenuates surface-associated growth of the Gram-negative pathogen Pseudomonas aeruginosa by both preventing biofilm maturation and killing bacteria within the established biofilm. CORM-2 treatment has an additive effect when combined with tobramycin, a drug commonly used to treat P. aeruginosa lung infections. CORM-2 inhibited biofilm formation and planktonic growth of the majority of clinical P. aeruginosa isolates tested, for both mucoid and non-mucoid strains....
Helicobacter pylori is a pathogen that establishes long life infections responsible for chronic gast...
Aims: Carbon monoxide-releasing molecules (CORMs) are being developed with the ultimate goal of safe...
Pseudomonas aeruginosa (P. aeruginosa) infection in the lung is common in patients with cystic fibro...
Chronic infections resulting from biofilm formation are difficult to eradicate with current antimicr...
Chronic infections resulting from biofilm formation are difficult to eradicate with current antimicr...
Carbon monoxide releasing molecules (CORMs) have been suggested as a new synthetic class of antimicr...
Antimicrobial resistance is a major public health risk that currently contributes to hundreds of tho...
<p>A) Crystal violet (CV) biomass staining decreases after CORM-2 exposure in a dose-dependent manne...
Antibiotic-resistant pathogenic bacteria pose a major, growing public health risk. Antibiotics affe...
<p>A) The addition of 100 µM CORM-2 to M9 liquid medium with glucose (left) prevents the growth of a...
La recherche de nouvelles molécules pour combattre Pseudomonas.aeruginosa est d'une grande importanc...
International audienceAIMS: Carbon monoxide (CO) delivered in a controlled manner to cells and organ...
La recherche de nouvelles molécules pour combattre Pseudomonas.aeruginosa est d'une grande importanc...
Helicobacter pylori is a pathogen that establishes long life infections responsible for chronic gast...
<p>A) The addition of NAC (1 mM) or L-cysteine (100 µM) to CORM-2 (100 µM) treated <i>P. aeruginosa<...
Helicobacter pylori is a pathogen that establishes long life infections responsible for chronic gast...
Aims: Carbon monoxide-releasing molecules (CORMs) are being developed with the ultimate goal of safe...
Pseudomonas aeruginosa (P. aeruginosa) infection in the lung is common in patients with cystic fibro...
Chronic infections resulting from biofilm formation are difficult to eradicate with current antimicr...
Chronic infections resulting from biofilm formation are difficult to eradicate with current antimicr...
Carbon monoxide releasing molecules (CORMs) have been suggested as a new synthetic class of antimicr...
Antimicrobial resistance is a major public health risk that currently contributes to hundreds of tho...
<p>A) Crystal violet (CV) biomass staining decreases after CORM-2 exposure in a dose-dependent manne...
Antibiotic-resistant pathogenic bacteria pose a major, growing public health risk. Antibiotics affe...
<p>A) The addition of 100 µM CORM-2 to M9 liquid medium with glucose (left) prevents the growth of a...
La recherche de nouvelles molécules pour combattre Pseudomonas.aeruginosa est d'une grande importanc...
International audienceAIMS: Carbon monoxide (CO) delivered in a controlled manner to cells and organ...
La recherche de nouvelles molécules pour combattre Pseudomonas.aeruginosa est d'une grande importanc...
Helicobacter pylori is a pathogen that establishes long life infections responsible for chronic gast...
<p>A) The addition of NAC (1 mM) or L-cysteine (100 µM) to CORM-2 (100 µM) treated <i>P. aeruginosa<...
Helicobacter pylori is a pathogen that establishes long life infections responsible for chronic gast...
Aims: Carbon monoxide-releasing molecules (CORMs) are being developed with the ultimate goal of safe...
Pseudomonas aeruginosa (P. aeruginosa) infection in the lung is common in patients with cystic fibro...